Grace Therapeutics, Inc. also files under GRCE; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Kohli Prashant | Chief Executive Officer, Director | Buy(P) | 100K | $2.14 | $214K |
| Sep 9, 2026 | Opaleye Management Inc. | 10% Owner | Buy(P) | 6K | $2.09 | $12K |
| Sep 8, 2026 | Opaleye Management Inc. | 10% Owner | Buy(P) | 9K | $2.10 | $20K |
| Aug 28, 2026 | Kumar Amresh | VP Program Management | Grant(A) | 36K | — | $0 |
| Aug 28, 2026 | DelAversano Robert J | Principal Financial Officer | Grant(A) | 34K | — | $0 |
| Aug 28, 2026 | Macdonald R. Loch | Chief Medical Officer | Grant(A) | 55K | — | $0 |
| Aug 28, 2026 | Kohli Prashant | Chief Executive Officer, Director | Grant(A) | 267K | — | $0 |
| Aug 14, 2026 | Opaleye Management Inc. | 10% Owner | Buy(P) | 12K | $2.09 | $24K |
| Jan 8, 2026 | Neugeboren Edward | Director | Grant(A) | 10K | — | $0 |
| Jan 8, 2026 | Davis A Brian | Director | Grant(A) | 10K | — | $0 |
| Jan 8, 2026 | Kavuru Vimal | Director | Grant(A) | 10K | — | $0 |
| Jan 8, 2026 | Kottayil George | Director | Grant(A) | 10K | — | $0 |
| May 9, 2025 | Kottayil George | Director | Grant(A) | 10K | — | $0 |
| May 9, 2025 | Kavuru Vimal | Director | Grant(A) | 10K | — | $0 |
| May 9, 2025 | Davis A Brian | Director | Grant(A) | 10K | — | $0 |
| May 9, 2025 | Neugeboren Edward | Director | Grant(A) | 10K | — | $0 |
| Apr 14, 2025 | Macdonald R. Loch | Chief Medical Officer | Grant(A) | 40K | — | $0 |
| Apr 14, 2025 | D'Andrea Carrie | VP Clinical Operations | Grant(A) | 30K | — | $0 |
| Apr 14, 2025 | Kohli Prashant | Chief Executive Officer, Director | Grant(A) | 225K | — | $0 |
| Apr 14, 2025 | DelAversano Robert J | Principal Financial Officer | Grant(A) | 20K | — | $0 |
| Apr 14, 2025 | Kumar Amresh | VP Program Management | Grant(A) | 30K | — | $0 |
| May 6, 2024 | Kumar Amresh | VP Program Management | Grant(A) | 20K | — | $0 |
| May 6, 2024 | D'Andrea Carrie | VP Clinical Operations | Grant(A) | 20K | — | $0 |
| May 6, 2024 | Kohli Prashant | Chief Executive Officer, Director | Grant(A) | 129K | — | $0 |
| May 6, 2024 | DelAversano Robert J | Principal Financial Officer | Grant(A) | 5K | — | $0 |
| May 6, 2024 | Macdonald R. Loch | Chief Medical Officer | Grant(A) | 25K | — | $0 |
| Dec 19, 2023 | Kottayil George | Director | Grant(A) | 23K | — | $0 |
| Dec 19, 2023 | Kavuru Vimal | Director, 10% Owner | Grant(A) | 10K | — | $0 |
| Dec 19, 2023 | Neugeboren Edward | Director | Grant(A) | 23K | — | $0 |
| Dec 19, 2023 | Davis A Brian | Director | Grant(A) | 23K | — | $0 |
| Dec 19, 2023 | Kohli Prashant | Chief Executive Officer, Director | Grant(A) | 42K | — | $0 |
| Sep 25, 2023 | Kavuru Vimal | Director, 10% Owner | Buy(P) | 676K | $1.85 | $1.3M |
| Sep 25, 2023 | Kavuru Vimal | Director, 10% Owner | Buy(P) | 423K | $0.13 | $55K |
| Aug 31, 2023 | Olds Donald | Director | Buy(P) | 381 | $2.05 | $781 |
| Jul 14, 2023 | Kohli Prashant | Chief Executive Officer | Grant(A) | 208K | — | $0 |
| Jul 14, 2023 | Kumar Amresh | VP Program Management | Grant(A) | 42K | — | $0 |
| Jul 14, 2023 | D'Andrea Carrie | VP Clinical Operations | Grant(A) | 42K | — | $0 |
| Jul 14, 2023 | Derby Michael | Director | Grant(A) | 13K | — | $0 |
| Jul 14, 2023 | Kavuru Vimal | Director | Grant(A) | 13K | — | $0 |
| Jul 14, 2023 | Macdonald R. Loch | Chief Medical Officer | Grant(A) | 60K | — | $0 |
| Jul 14, 2023 | Olds Donald | Director | Grant(A) | 13K | — | $0 |
| Sep 28, 2022 | Canan John | Director | Grant(A) | 45K | — | $0 |
| Sep 28, 2022 | Olds Donald | Director | Grant(A) | 45K | — | $0 |
| Sep 28, 2022 | Kavuru Vimal | Director | Grant(A) | 45K | — | $0 |
| Sep 28, 2022 | Derby Michael | Director | Grant(A) | 85K | — | $0 |
| Jun 22, 2022 | Kottayil George | COO, US | Grant(A) | 50K | — | $0 |
| Jun 22, 2022 | Ford Brian D. | CHIEF FINANCIAL OFFICER | Grant(A) | 165K | — | $0 |
| Jun 22, 2022 | D'Alvise Janelle | PRESIDENT & CEO, Director | Grant(A) | 560K | — | $0 |
| Jun 22, 2022 | Lemieux Pierre | COO, Canada & CSO | Grant(A) | 165K | — | $0 |
| Nov 12, 2021 | D'Alvise Janelle | PRESIDENT & CEO, Director | Grant(A) | 656K | — | $0 |
| Nov 12, 2021 | Carter Roderick Noel | Director | Grant(A) | 42K | — | $0 |
| Nov 12, 2021 | Canan John | Director | Grant(A) | 42K | — | $0 |
| Nov 12, 2021 | Haseltine William A | Director | Grant(A) | 42K | — | $0 |
| Nov 12, 2021 | Ford Brian D. | CHIEF FINANCIAL OFFICER | Grant(A) | 288K | — | $0 |
| Nov 12, 2021 | Kavuru Vimal | Director | Grant(A) | 42K | — | $0 |
| Nov 12, 2021 | Lemieux Pierre | COO, Canada & CSO | Grant(A) | 288K | — | $0 |
| Nov 12, 2021 | Olds Donald | Director | Grant(A) | 42K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Grace Therapeutics, Inc., SEC CIK 0001444192. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under ACST and shows every filing by that issuer (also filed as GRCE).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-15. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for ACST